Welcome to our dedicated page for Korro Bio SEC filings (Ticker: KRRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Korro Bio, Inc. (KRRO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer listed on Nasdaq. Korro focuses on RNA-editing genetic medicines, and its filings with the U.S. Securities and Exchange Commission offer detailed information on clinical programs, collaborations, restructuring actions, and executive changes that complement its press releases.
Investors can review Forms 10-K and 10-Q for narrative and financial discussion of Korro’s development of KRRO-110 for Alpha-1 Antitrypsin Deficiency, the REWRITE Phase 1/2a clinical trial design, and the OPERA RNA editing platform. These periodic reports also describe risk factors, research and development spending, and collaboration revenue, including from its research collaboration and license agreement with Novo Nordisk A/S.
Current reports on Form 8-K are particularly relevant for tracking material events at Korro. Recent 8-K filings describe the amendment to the Novo Nordisk collaboration establishing a 12‑month pause in research and development activities, strategic restructuring and workforce reductions intended to extend cash runway, and executive transitions such as the resignation of the Chief Financial Officer and Chief Medical Officer and related separation agreements. Other 8-Ks outline compensatory arrangements, including amended employment agreements and equity awards.
Users can also monitor proxy statements and compensation disclosures referenced in Korro’s 8-Ks for background on executive employment terms, as well as any Form 4 insider transaction reports that may be filed to reflect equity grants or option exercises under the company’s stock plans. Stock Titan enhances these filings with AI-powered summaries that explain key points in accessible language, highlight important sections of long reports, and help readers quickly understand how new filings may relate to Korro’s RNA-editing pipeline, collaborations, and capital allocation.
Korro Bio announced multiple changes. The company and Novo Nordisk agreed to pause their research collaboration and license agreement for 12 months. During this hold period, all research and development obligations are suspended without liability or payment for either party, and Korro will wind down related activities. Novo Nordisk will reimburse certain wind-down costs, while confidentiality, exclusivity, termination terms, and Novo Nordisk’s substitution right remain in effect.
Korro implemented a strategic restructuring, reducing its workforce by approximately 34%. It estimates $2.4 million in one-time restructuring charges, mostly expected in the quarter ending December 31, 2025. Chief Medical Officer Olukemi A. Olugemo, M.D. resigned effective November 12, 2025, and will advise for three months; the post-termination option exercise period for vested options is extended through April 30, 2027. Korro also furnished a press release with financial results for the quarter ended September 30, 2025.
Korro Bio reported that Chief Financial Officer Vineet Agarwal plans to resign effective October 17, 2025 to pursue another opportunity. He has agreed to remain available as an advisor for 30 days to help with the transition. His separation is being handled under his November 2023 employment agreement, with a Separation Agreement providing benefits outside a change in control context, and his vested stock options as of October 17, 2025 may be exercised through March 31, 2027. The company states his departure is not due to any disagreement over management, operations, policies, or practices.
The board has appointed President and Chief Executive Officer Ram Aiyar to serve additionally as interim Chief Financial Officer and principal financial officer starting October 17, 2025. He will not receive additional compensation for these interim duties, and the company notes there are no special arrangements, family relationships, or related-party transactions tied to his appointment. The Separation Agreement with Mr. Agarwal is filed as an exhibit.
Korro Bio received a Schedule 13G/A disclosing that members of the Point72/Steven A. Cohen group collectively beneficially own 816,905 shares, representing 8.7% of Korro Bio's common stock as of the close of business on June 30, 2025. The filing breaks ownership across affiliated entities: Point72 Asset Management and Point72 Capital Advisors each report shared voting and dispositive power over 540,074 shares (5.8% each at the reporting-person level), while certain Point72 affiliates each report 276,831 shares (2.9%). No reporting person claims sole voting or dispositive power; the filing states the holdings were not acquired to change or influence control.
Korro Bio, Inc. Schedule 13G/A shows Deep Track Capital, Deep Track Biotechnology Master Fund, Ltd., and David Kroin jointly report beneficial ownership of 277,966 common shares, equal to 2.96% of the company's outstanding common stock. The filers report no sole voting or dispositive power and shared voting and dispositive power for the full amount, and include a certification that the shares were not acquired to change or influence control. The percentage is calculated using 9,390,492 shares outstanding as referenced in the issuer's disclosure.
AllianceBernstein L.P. reports beneficial ownership of 7,700 shares of Korro Bio Inc. common stock, representing 0.1% of the class. The filing states AllianceBernstein has sole voting and sole dispositive power over all 7,700 shares and holds the position in client discretionary investment advisory accounts for investment purposes. The filing notes AllianceBernstein is majority owned by Equitable Holdings but operates under independent management and that Equitable reports ownership separately. The statement affirms the position was not acquired to influence control of Korro Bio.
Korro Bio reported clinical progress alongside continued cash burn. The company recognized $4.0 million of collaboration revenue from Novo Nordisk and reported dosing of first participants in its Phase 1/2a REWRITE trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency, with interim single-ascending dose data expected in the second half of 2025 and orphan drug designations from the FDA and EMA. As of June 30, 2025 the company held $119.6 million of cash, cash equivalents and marketable securities, which management expects will fund operations into 2027.
However, losses remain significant: net loss was $49.2 million for the six months ended June 30, 2025 and the accumulated deficit was $315.7 million. Management executed a 19% workforce reduction and recorded severance charges. The balance sheet shows total assets of $180.4 million and operating lease liabilities with a present value of $44.6 million. The company states additional financing may be required to continue development.
Korro Bio, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025 as Exhibit 99.1 to a Form 8-K and included a Cover Page Interactive Data file as Exhibit 104. The Form 8-K states the press release is being furnished and expressly notes that the information, including Exhibit 99.1, is not to be deemed "filed" for purposes of Section 18 of the Securities Exchange Act.
The 8-K itself contains no financial figures or tables; readers must review Exhibit 99.1 for the company’s reported results. The report also confirms Korro’s common stock trades under the symbol KRRO on The Nasdaq Capital Market.